Please Wait.....
Report
Global AL Amyloidosis Treatment Market Report and Forecast 2023-2031
Market Report I 2023-03-15 I 147 Pages I EMR Inc.
Global AL Amyloidosis Treatment Market Report and Forecast 2023-2031
Global AL Amyloidosis Treatment Market Outlook
The global AL amyloidosis treatment market size was valued at USD 2.25 billion in 2022 and is projected to grow at a CAGR of 7.60% during the forecast period of 2023-2031 to reach a value of USD 4.35 billion by 2031. The market growth can be attributed to the increasing prevalence of AL amyloidosis and the rising awareness about the disease.
Global AL Amyloidosis Treatment Market: Introduction
AL amyloidosis treatment refers to the medical care provided to individuals with AL amyloidosis, a rare disease characterized by the accumulation of abnormal proteins called amyloids in organs and tissues. The treatment options include chemotherapy, stem cell transplantation, and supportive care, such as pain management and nutrition therapy. The increasing prevalence of AL amyloidosis, along with the rising awareness of the disease, is driving the demand for AL amyloidosis treatment. Other factors such as increasing research and development, and the growing demand for innovative treatment options are also expected to drive market growth.
Rapid advancements in technology have played a significant role in the growth of the AL amyloidosis treatment market. The development of novel therapies, such as monoclonal antibodies and targeted therapies, has improved the treatment options for AL amyloidosis patients. This has led to better outcomes and increased the demand for AL amyloidosis treatment. The market is expected to continue to grow in the coming years as the awareness about AL amyloidosis continues to increase, and new treatment options are developed to meet the needs of patients with the disease.
AL Amyloidosis Epidemiology
AL amyloidosis affects approximately 8-12 people per million worldwide, with an estimated 3,000-4,000 new cases diagnosed annually in the United States alone. The disease can affect people of all ages and genders, but it is more common in older adults and slightly more prevalent in men.
Global AL Amyloidosis Treatment Market Segmentations
The market can be segmented based on treatment type, diagnosis type, route of administration, distribution channel, and region:
Market Breakup by Treatment Type
- Corticosteroids
- Proteasome Inhibitors
- Cytotoxic Chemotherapy
- Immunomodulatory Drugs
- Autologous Hematopoietic Stem Cell Transplantation
- Risk-adapted Melphalan
- Others
Breakup by Diagnosis Type
- Blood Tests
- Magnetic Resonance Imaging (MRI)
- Ultrasound
- Biopsy
- Others
Breakup by Route of Administration
- Oral
- Injectables
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Market Breakup by Region
- North America
? United States of America
? Canada
- Europe
? United Kingdom
? Germany
? France
? Italy
? Others
- Asia Pacific
? China
? Japan
? India
? ASEAN
? Australia
? Others
- Latin America
? Brazil
? Argentina
? Mexico
? Others
- Middle East and Africa
? Saudi Arabia
? United Arab Emirates
? Nigeria
? South Africa
? Others
AL Amyloidosis Treatment Market Analysis
The global market has experienced significant growth over the past few years, driven by factors such as the increasing prevalence of AL amyloidosis and rising awareness about the disease. One key driver of the AL amyloidosis treatment market growth is the increasing prevalence of AL amyloidosis. North America is currently the largest market for AL amyloidosis treatment, accounting for a significant share of the global market. The region's large market share is driven by factors such as a high prevalence of AL amyloidosis, a well-established healthcare infrastructure, and strong investment in research and development. In addition, the growing adoption of novel therapies and targeted treatments is further driving the growth of the market in North America.
Europe is also a significant market for AL amyloidosis treatment, with countries such as the UK, Germany, and France leading the way. The region's market growth is driven by factors such as a large population base, increasing awareness of AL amyloidosis, and government initiatives to address rare diseases. Additionally, the region has a well-established healthcare system, which supports the delivery of AL amyloidosis treatment.
Asia Pacific is another region that is experiencing significant growth in the AL amyloidosis treatment market. The region's market growth is driven by factors such as a large population base, increasing awareness of AL amyloidosis, and the growing adoption of advanced treatment options. In addition, government initiatives to address rare diseases and improve healthcare infrastructure are helping to drive the growth of the market in the region.
Key Players in the Global AL Amyloidosis Treatment Market
The report provides a detailed analysis of the key players involved in the AL amyloidosis treatment market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:
- Janssen Global Services, LLC
- Caelum Biosciences (AstraZeneca)
- Oncopeptides, Inc.
- Bristol-Myers Squibb Company
- Acrotech Biopharma, Inc.
- Sanofi
- Prothena Corporation plc
- Alexion Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- GSK plc
- Sorrento Therapeutics, Inc.
- Alnylam Pharmaceuticals, Inc.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 AL Amyloidosis Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global AL Amyloidosis Treatment Market
8.1 Global AL Amyloidosis Treatment Market Overview
8.2 Global AL Amyloidosis Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global AL Amyloidosis Treatment Market Historical Value (2016-2022)
8.2.1.2 Global AL Amyloidosis Treatment Market Forecast Value (2023-2031)
8.2.2 Global AL Amyloidosis Treatment Market by Treatment Type
8.2.2.1 Market Overview
8.2.2.1.1 Corticosteroids
8.2.2.1.2 Proteasome Inhibitors
8.2.2.1.3 Cytotoxic Chemotherapy
8.2.2.1.4 Immunomodulatory Drugs
8.2.2.1.5 Autologous Hematopoietic Stem Cell Transplantation
8.2.2.1.6 Risk-adapted Melphalan
8.2.2.1.7 Others
8.2.3 Global AL Amyloidosis Treatment Market by Diagnosis Type
8.2.3.1 Market Overview
8.2.3.1.1 Blood Tests
8.2.3.1.2 Magnetic Resonance Imaging (MRI)
8.2.3.1.3 Ultrasound
8.2.3.1.4 Biopsy
8.2.3.1.5 Others
8.2.4 Global AL Amyloidosis Treatment Market by Route of Administration
8.2.4.1 Market Overview
8.2.4.1.1 Oral
8.2.4.1.2 Injectables
8.2.4.1.3 Others
8.2.5 Global AL Amyloidosis Treatment Market by Distribution Channel
8.2.5.1 Market Overview
8.2.5.1.1 Hospital Pharmacies
8.2.5.1.2 Online Pharmacies
8.2.5.1.3 Retail Pharmacies
8.2.6 Global AL Amyloidosis Treatment Market by Region
8.2.6.1 Market Overview
8.2.6.1.1 North America
8.2.6.1.2 Europe
8.2.6.1.3 Asia Pacific
8.2.6.1.4 Middle East and Africa
8.2.6.1.5 Latin America
9 North America AL Amyloidosis Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe AL Amyloidosis Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific AL Amyloidosis Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America AL Amyloidosis Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa AL Amyloidosis Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global AL Amyloidosis Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter's Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Janssen Global Services, LLC
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Caelum Biosciences (AstraZeneca)
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Oncopeptides, Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Bristol-Myers Squibb Company
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Acrotech Biopharma, Inc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Sanofi
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Prothena Corporation plc
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Alexion Pharmaceuticals, Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Takeda Pharmaceutical Company Limited
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 GSK plc
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Sorrento Therapeutics, Inc.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
16 AL Amyloidosis Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security